SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-KSB

[X]  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES ACT OF
     1934

                        For the year ended July 31, 2004

                        Commission File Number: 333-68942

                               CRITICAL CARE, INC.
              ----------------------------------------------------
             (Exact name of registrant as specified in its charter)

            Nevada                                                88-0490720
 ------------------------------                               -----------------
(State or other jurisdiction of                              (I.R.S. Employer
 incorporation or organization)                              Identification No.)

                         6646 Indian School Road, N.E.,
                          Albuquerque, New Mexico 87110
           -----------------------------------------------------------
          (Address, including zip code, of principal executive offices)

                                 (505) 837-2020
               --------------------------------------------------
              (Registrant's telephone number, including area code)


                               Lasik America, Inc.
          ------------------------------------------------------------
         (Former name or former address, if changed since last report.)


         Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

(1)Yes     X     No
         -----        -----

(2)Yes     X     No
        -----         -----

                      APPLICABLE ONLY TO CORPORATE ISSUERS:

Transitional Small Business Disclosure Format (Check one):  Yes[ ]  No[X]

     Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. [ ]

     The issuer' revenue for the fiscal year ended July 31, 2004 was $926,652.

     The aggregate market value of the voting stock held by non-affiliates of
the Registrant as of July 31, 2004 was $270,761 using the closing price of $0.25
on July 30, 2004 (1,083,043 shares of common stock).

     State the number of shares outstanding of each of the issuer's class of
common equity, as of the latest practicable date: At November 1, 2004, the
issuer had outstanding 9,226,043 shares of Common Stock, no par value per share.

<PAGE>


                     DOCUMENTS INCORPORATED BY REFERENCE:

         A list of Exhibits and documents to be incorporated by reference to
this Annual Report on Form 10-KSB begins on page 17.


Forward-Looking Statements

Certain statements under the caption "Management's Discussion and Analysis of
Financial Condition and Results of Operations" and elsewhere in this Annual
Report constitute "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors which may cause
the actual results, performance or achievements of the Company, or industry
results, to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking statements. Such
factors include, among others, the Company's ability to attract customers,
general economic and business conditions with respect to the business of the
Company, changes in government regulations, competition and the ability of the
Company to implement its business strategy and other risks discussed in this
Form 10-KSB and the registration statement on Form SB-2 filed with the
Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this Form 10-KSB.
Moreover, whether or not stated in connection with a forward-looking statement,
the Company undertakes no obligation to correct or update a forward-looking
statement should the Company later become aware that it is not likely to be
achieved. If the Company were to update or correct a forward-looking statement,
investors and others should not conclude that the Company will make additional
updates or corrections thereafter.


<PAGE>


                               Critical Care, Inc.
                             2004 FORM 10-KSB REPORT


                                TABLE OF CONTENTS
                                -----------------
Part   I                                                                    Page
--------                                                                    ----

Item 1.           Description of the Business                                1
Item 2.           Description of Property                                    4
Item 3            Legal Proceedings                                          4
Item 4            Submission of Matters to a Vote of Security Holders        4

Part   II
---------
Item 5            Market for Registrant's Common Equity and Related

                  Stockholder Matters                                        5
Item 6            Management's Discussion and Analysis of Financial
                  Condition and Results of Operations                        6
Item 7            Financial Statements                                       10
Item 8            Changes in and Disagreements with Accountants on Return
                  Accounting and Financial Disclosure                        10
Item 8A           Controls and Procedures                                    10


Part   III
----------
Item 9            Directors, Executive Officers, Promoters and Control
                  Persons of the Registrant; Compliance with Section
                  16(a) of  the Exchange Act                                 12
Item 10           Executive Compensation                                     14
Item 11           Security Ownership of Certain Beneficial Owners And
                  Management and Related Stockholder Matters                 15
Item 12           Certain Relationships and Related Transactions             16
Item 13           Exhibits and Reports on Form 8-K                           17
Item 14           Principal Accountant Fees and Services                     17
                  Signatures                                                 18

<PAGE>


PART I
------

ITEM 1.       DESCRIPTION OF THE BUSINESS

Critical Care, Inc. f/k/a Lasik America, Inc. ("Critical" or the "Company")
provides laser vision correction procedures to individuals, at its New Mexico
Center Office in Albuquerque, New Mexico. Critical's ophthalmologist provides
these services using state-of-the-art excimer laser technology. Critical opened
its first Critical center in Albuquerque, New Mexico in May 2001. Management has
changed the Company's business plans from the Lasik business into the dialysis
business with the acquisition of Salus Holding, Inc. and its belief that the
dialysis business will offer the Company a greater opportunity for growth and
long term success.

Corporate background
--------------------

The Company was incorporated in Nevada on March 21, 2001 as Lasik America, Inc.
and since that time has been providing laser vision correction services using
the VISX, Incorporated excimer laser. On October 26, 2004, the Company changed
its name to "Critical Care, Inc." by filing an amendment to its certificate of
incorporation with the Secretary of State of the State of Nevada.

Business Strategy
-----------------

On August 5, 2004, a subsidiary of the Company, Lasik Acquisition Corp.,
consummated its merger with Salus Holding, Inc. ("Salus"). Pursuant to the
merger agreement, the shareholders of Salus have been issued 2,000,000 shares of
common stock of the Company.

The sole shareholder of Salus, Homeland Security Technology, Inc., was issued
2,000,000 shares of Critical's Common Stock that approximated 47.3 percent of
the outstanding shares of Critical calculated on a fully diluted basis at the
date of issuance. In addition, as of August 4, 2004, Ernest B. Remo, former
President and Chairman of the Board of Directors of Salus, has assumed the
position of Chief Executive Officer and Chairman of the Board of Directors of
Critical. Howard Silverman assumed the position of President and member of the
Board of Directors of Critical.

Salus is the sole shareholder in Icon Salus S.r.l., a company formed under the
laws of Italy ("Icon Salus"). Icon Salus is developing a dialysis clinic in
Italy as well as the rights to acquire additional dialysis clinics. Management
believes that expanding into the dialysis business will offer the Company a
greater opportunity for growth and long term success. The Company is currently
seeking other opportunities to expand into this business.

The decision to consummate the Salus transaction was prompted by the lack of
dialysis facilities in Italy as well as world wide. Management believes that
there is a worldwide growth in kidney disease worldwide which creates a great
and continually increasing demand for dialysis services. Management has
determined that the dialysis business offers greater return on investment than
the Lasik business.


Salus has leased a facility and is in the process of opening a dialysis facility
in Amaseno, Italy. Management expects that the initial projections for the
Amaseno clinic will include treating between 20 and 30 patients for a total of
240 to 360 treatments per month. Management anticipates that this will result in
gross revenues from the Amaseno clinic of between Euro 1,000,000 and Euro
1,500,000 (US$1,300,000 and US$1,950,000) in the first year of operations. The
Italian government health care system reimburses facilities such as the Amaseno
facility 100% of the patients costs of such dialysis treatments. The Amaseno
facility is scheduled to commence operations within 60 days.

Management plans to open one clinic per year in Europe as well as continuing to
seek acquisitions or established clinics.

                                        1

<PAGE>


On November 1, 2004, the Company acquired certain rights to purchase a group of
five dialysis clinics from Icon Veneto srl, an Italian company, pursuant to a
rights purchase agreement. The rights purchased consist of a binding letter of
intent assigned to the Company pursuant to the agreement. Pursuant to the rights
purchase agreement the Company issued to Icon Veneto 100,000 shares of preferred
stock of the Company. The preferred stock is convertible into 10,000,000 shares
of common stock of the Company. The five dialysis clinics which are the subject
of the rights purchase agreement have established revenues of over Euro
4,000,000 (US$5,250,000). Management is currently negotiating the terms of the
purchase of the five clinics and expects to consummate the purchase of the
clinics within six months.

Management plans to open one clinic per year in Europe as well as continuing to
seek acquisitions of established clinics. In addition, Management is seeking
acquisitions of dialysis clinics in the United States

Dialysis Business
-----------------

Kidneys act as a filter removing harmful substances and excess water from the
blood, enabling the body to maintain proper and healthy balances of chemicals
and water. Chronic kidney failure, ESRD, results from chemical imbalance and
buildup of toxic chemicals, and is a state of kidney disease characterized by
advanced irreversible renal impairment. ESRD is a likely consequence of
complications resulting from diabetes, hypertension, advanced age, and specific
hereditary, cystic and urological diseases. ESRD patients, in order to survive,
must either obtain a kidney transplant, which procedure is limited due to lack
of suitable kidney donors and the incidence of rejection of transplanted organs,
or obtain dialysis treatments for the rest of their lives.

Based upon information published by CMS, the number of ESRD patients requiring
dialysis treatments in the United States is approximately 300,000, and continues
to grow at a rate of approximately 6% a year. This is thought to be attributable
primarily to the aging of the population and greater patient longevity as a
result of improved dialysis technology. The statistics further reflect
approximately 4,200 dialysis facilities, with the current annual cost of
treating ESRD patients in the United States at approximately $22.8 billion.

ESRD Treatment Options
----------------------

Treatment options for ESRD patients include (1) hemodialysis, performed either
at (i) an outpatient facility, or (ii) inpatient hospital facility, or (iii) the
patient's home; (2) peritoneal dialysis, either continuous ambulatory peritoneal
dialysis or continuous cycling peritoneal dialysis; and/or (3) kidney
transplant. A significant portion of ESRD patients receive treatments at
non-hospital owned outpatient dialysis facilities (according to CMS,
approximately 80%) with most of the remaining patients treated at home through
hemodialysis or peritoneal dialysis. Patients treated at home are monitored by a
designated outpatient facility.

The most prevalent form of treatment for ESRD patients is hemodialysis, which
involves the use of an artificial kidney, known as a dialyzer, to perform the
function of removing toxins and excess fluids from the bloodstream. This is
accomplished with a dialysis machine, a complex blood filtering device which
takes the place of certain functions of the kidney and also controls external
blood flow and monitors the toxic and fluid removal process. The dialyzer has
two separate chambers divided by a semi-permeable membrane, and simultaneously
with the blood circulating through one chamber, dialyzer fluid is circulated
through the other chamber. The toxins and excess fluid pass through the membrane
into the dialysis fluid. On the average, patients usually receive three
treatments per week with each treatment taking three to five hours. Dialysis
treatments are performed by teams of licensed nurses and trained technicians
pursuant to the staff physician's instructions.

Home hemodialysis treatment requires the patient to be medically suitable and
have a qualified assistant. Additionally, home hemodialysis requires training
for both the patient and the patient's assistant, which usually encompasses four

                                       2

<PAGE>


to eight weeks. Dialysis Corporation of America does not currently provide home
hemodialysis (non-peritoneal) services. The use of conventional home
hemodialysis has declined and is minimal due to the patient's suitability and
lifestyle, the need for the presence of a caregiver and a dialysis machine at
home, and the higher expense involved as compared with continuous ambulatory
peritoneal dialysis.

A second home treatment for ESRD patients is peritoneal dialysis. There are
several variations of peritoneal dialysis, the most common being continuous
ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis. All
forms of peritoneal dialysis use the patient's peritoneal (abdominal) cavity to
eliminate fluid and toxins from the patient. Continuous ambulatory peritoneal
dialysis utilizes dialysis solution infused manually into the patient's
peritoneal cavity through a surgically-placed catheter. The solution is allowed
to remain in the abdominal cavity for a three to five hour period and is then
drained. The cycle is then repeated. Continuous cycling peritoneal dialysis is
performed in a manner similar to continuous ambulatory peritoneal dialysis, but
utilizes a mechanical device to cycle the dialysis solution while the patient is
sleeping. Peritoneal dialysis is the third most common form of ESRD therapy
following center hemodialysis and renal transplant.

While kidney transplantation, another treatment option for patients with ESRD,
is typically the most desirable form of therapeutic intervention, the scarcity
of suitable donors and possibility of donee rejection limits the availability of
this surgical procedure as a treatment option.

Employees
---------

At July 31, 2004, the Company operated with approximately 5 employees and
consultants. There is no collective bargaining agreement in place.

Corporate Information
---------------------

We were incorporated in Nevada on on March 21, 2001 as Lasik America, Inc. On
October 26, 2004, the Company changed its name to "Critical Care, Inc." by
filing an amendment to its certificate of incorporation with the Secretary of
State of the State of Nevada. On August 5, 2004, a subsidiary of the Company,
Lasik Acquisition Corp., consummated its merger with Salus Holding, Inc.
("Salus"). Pursuant to the merger agreement, the shareholders of Salus have been
issued 2,000,000 shares of common stock of the Company.

The sole shareholder of Salus, Homeland Security Technology, Inc., was issued
2,000,000 shares of Critical's Common Stock that approximate 47.3 percent of the
outstanding shares of Critical calculated on a fully diluted basis as of the
date of issuance. In addition, as of August 4, 2004, Ernest B. Remo, former
President and Chairman of the Board of Directors of Salus, has assumed the
position of Chief Executive Officer and Chairman of the Board of Directors of
Critical. Howard Silverman assumed the position of President and member of the
Board of Directors of Critical.

Salus is the sole shareholder in Icon Salus S.r.l., a company formed under the
laws of Italy ("Icon Salus"). Icon Salus is developing a dialysis clinic in
Italy as well as the rights to acquire additional dialysis clinics.

On October 28, 2004, the Company acquired certain rights to purchase a group of
five dialysis clinics from Icon Veneto srl, an Italian company, pursuant to a
rights purchase agreement. The rights purchased consist of a binding letter of
intent assigned to the Company pursuant to the agreement. Pursuant to the rights
purchase agreement the Company issued to Icon Veneto 100,000 shares of preferred
stock of the Company. The preferred stock is convertible into 10,000,000 shares
of common stock of the Company. The five dialysis clinics which are the subject
of the rights purchase agreement have established revenues of over Euro
4,000,000 (US$5,250,000). Management is currently negotiating the remaining
terms of the purchase of the five clinics and expects to consummate the purchase
of the clinics within six months.

                                       3

<PAGE>


Our principal executive offices are located at 6646 Indian School Road, N.E.,
Albuquerque, New Mexico 87110. Our telephone number is (505) 837-2020, fax
number is (505) 837-9111.

ITEM 2.  DESCRIPTION OF PROPERTY

The Company leases a 2,200 square foot facility in New Mexico for a lease of $
3,470 per month. The Company also leases a 3,000 square foot dialysis facility
in Amaseno, Italy for Euro 1000 per month.

ITEM 3.  LEGAL PROCEEDINGS

On or about December 17, 2002, a charge of discrimination against the Company
was filed with the United States Equal Employment Opportunity Commission (the
"EEOC") by Donna L. Smith-Howard, alleging that she was terminated without a
valid reason and denied severance benefits in violation of Title VII of the
Civil Rights Act of 1964 as amended.

The Company has responded to and denied the charge, stating that Ms.
Smith-Howard, a probationary employee, was terminated due to the elimination of
her position because of a lack of sufficient business that would justify her
position, and the duties assigned to her were then reassigned to another
employee with greater seniority.

The Company also denied Ms. Smith-Howard's factually incorrect allegations that
another employee was given a severance package and that she was replaced by
another employee. This matter was under investigation and was pending in the
EEOC office located at 1919 Smith Street, Houston, Texas, 77002. The Company
vigorously contested the charge, and it received a favorable outcome and a
finding of no probable cause by the EEOC.

A complaint was filed against the Company on March 31, 2003 by Mary Ratchford, a
former employee. Ms. Ratchford contends that she was fired as an employee
inspite of an employment contract that she had with the Company. The Company has
responded to the charge stating that she violated her contract through
non-performance and dishonesty. The Company intends to vigorously contest the
charge and it expects a favorable outcome. It may, in the near future, file a
counterclaim against Ms. Ratchford.

Critical is involved in other various legal proceedings and claims incident to
the normal conduct of its business. Critical believes that such legal
proceedings and claims, individually and in the aggregate, are not likely to
have a material adverse effect on its financial position or results of
operations.

Item 4.  Submission Of Matters To A Vote Of Security Holders

On October 26, 2004, stockholders representing a majority of the issued and
outstanding common stock of the Company executed a written consent providing for
an amendment to the Company's Certificate of Incorporation changing its name to
Critical Care, Inc.

                                       4

<PAGE>


                                     PART II
Item 5.  Market for Registrant's Common Equity and Related Stockholder Matters

Common Stock

From March 24, 2004 until October 27, 2004, Critical's Common Stock has traded
on the over-the-counter electronic bulletin board under the symbol "LSIK.OB". On
October 27, 2004, the Company's trading symbol was changed to "CTCC.OB" to
reflect the name change. The price ranges presented below represent the highest
and lowest quoted sales prices during 3rd and 4th quarter of 2004 which the
Company was traded as reported by Nasdaq. The quotes represent prices between
dealers and do not reflect mark-ups, markdowns or commissions and therefore may
not necessarily represent actual transactions.

         Year         Period                       Sales Information
         ----         ------                       -----------------

                                           High                       Low
                                           ----                       ---
         2004         3rd Quarter          $ 1.75                     $ 0.75
                      4rd Quarter          $ 1.84                     $ 0.25

As reported by the Nasdaq OTC Bulletin Board, on July 31, 2004 the closing price
of the Common Stock was $ 0.25 per share.

Stockholders


At July 31, 2004 there were 2,226,043 shares outstanding and approximately 27
holders of record of Common Stock. We believe there is in excess of 30
beneficial owners of our Common Stock, some of whose shares are held in street
name.

On August 5, 2004, a subsidiary of the Company, Lasik Acquisition Corp.,
consummated its merger with Salus Holding, Inc. ("Salus"). Pursuant to the
merger agreement, the shareholders of Salus have been issued 2,000,000 shares of
common stock of the Company. The sole shareholder of Salus, Homeland Security
Technology, Inc., was issued 2,000,000 shares of Critical's Common Stock that
approximate 47.3 percent of the outstanding shares of Critical calculated on a
fully diluted basis at the date of issuance.

On October 28, 2004, the Company acquired certain rights to purchase a group of
five dialysis clinics from Icon Veneto srl, an Italian company, pursuant to a
rights purchase agreement. Pursuant to the rights purchase agreement the Company
issued to Icon Veneto 100,000 shares of preferred stock of the Company. The
preferred stock is convertible into 10,000,000 shares of common stock of the
Company. The five dialysis clinics which are the subject of the rights purchase
agreement have established revenues of over Euro 4,000,000 (US$5,250,000).

At November 1, 2004 there were 9,226,043 shares outstanding; and 100,000 shares
of preferred stock outstanding. (19,326,043 shares of common stock outstanding
on a fully diluted basis)

Dividend Policy

We have not paid, and our board of directors does not presently intend to
declare, any dividends on our Common Stock in the foreseeable future. We
anticipate that all of our earnings and other resources, if any, will be
retained by us for investment in our business.

                                       5

<PAGE>
<TABLE>
<CAPTION>


Securities Authorized for Issuance Under Equity Compensation Plans

The following table provides information as of July 31, 2004 about Critical's
common stock that may be issued upon the exercise of options, warrants and
rights under all of the Company's existing equity compensation plans.

                          Number of             Weighted-average        Number of Securities
                          securities to         exercise price of       remaining
                          be issued             outstanding             available for
                          upon                  options, warrants       future issuance
                          exercise of           and rights              under equity
                          outstanding                                   compensation plans
                          options,                                      (excluding securities
                          warrants and                                  reflected in column
                          rights                                        (a)
                          --------------------------------------------------------------------
<S>                          <C>                       <C>                     <C>
Equity Compensation
Plans approved by
Security holders

2004 Stock Award
and Incentive Plan            0                        0                        0

Equity Compensation
Plan not approved by
Security holders              0                        0                        0
----------------------------------------------------------------------------------------------
Total                         0                        0                        0
----------------------------------------------------------------------------------------------

Recent Sales of Unregistered Securities

On August 18, 2004, Critical's' 2004 Stock Award & Incentive Plan was approved
by the Board of Directors. A total of 5,000,000 shares of common stock were
reserved and available for grant under the 2004 Plan. As of November 1, 2004,
5,000,000 shares were issued pursuant to the plan.


On August 5, 2004, a subsidiary of the Company, Lasik Acquisition Corp.,
consummated its merger with Salus Holding, Inc. ("Salus"). Pursuant to the
merger agreement, the shareholders of Salus have been issued 2,000,000 shares of
common stock of the Company. The sole shareholder of Salus, Homeland Security
Technology, Inc., was issued 2,000,000 shares of Critical's Common Stock that
approximated 47.3 percent of the outstanding shares of Critical calculated on a
fully diluted basis at the date of issuance.


Item 6.  Management's Discussion and Analysis of Financial Condition and
Results of Operation

The following information should be read in conjunction with the information in
Item 7, Financial Statements, and other information regarding our financials
performance for the period covered by this report included elsewhere in this
report. The following discussions and other parts of this report may contain
forward-looking statements that involve risks and uncertainties. Our actual
results may differ significantly from the results discussed in those
forward-looking statements. Factors that might cause such differences include,
but are not limited to, our history of unprofitability and the uncertainty of
our profitability, our ability to develop and introduce new services and
products, the uncertainty of market acceptance of those services or products,
our potential reliance on collaborative partners, our limited sales and

                                       6
</TABLE>

<PAGE>


marketing experience, the highly competitive industries in which we operate and
general economic and business conditions, some or all of which may be beyond our
ability to control.

The following management discussion and analysis of financial condition and
results of operations should be read in conjunction with our financial
statements and accompanying notes and the other financial information included
elsewhere in this report.

Overview

We are a medical services company that focuses on delivering laser vision
correction surgical procedures to consumers. Our affiliated and employed doctors
provide medical care to our clients and we provide the necessary equipment,
technical staff, administrative services and the excimer laser, needed for the
delivery of laser eye surgery to our clients. We do not practice medicine,
rather our affiliated and employed doctors deliver medical care and treatment to
eye surgery patients.

We were incorporated on March 21, 2001 as LASIK America, Inc. In October 1995
and in March 1996, the United States Food and Drug Administration approved the
use of excimer lasers manufactured by Summit Technology, Inc. and VISX, Inc., to
treat low to moderate nearsightedness. In May 2001, we opened our first excimer
laser center in Albuquerque, New Mexico.

Our doctors perform laser vision correction surgery procedures in our New Mexico
center office. We provide our ophthalmologist and optometrist with
state-of-the-art equipment and facilities as well as support services necessary
to perform vision correction procedures. At present we have one employed
ophthalmologist and one employed optometrist in our center. Although we have no
written agreements with these doctors, we have agreed to compensate our
ophthalmologist at a rate of $200,000 per year and our optometrist at $500 per
day.

Our doctors perform surgery on clients of our center, which includes delivery of
pre and post-operative care. Our doctors also perform surgery on clients at our
center where co-managing optometrists perform the pre and post-operative care.

To date, the supply of our excimer laser and related equipment has come through
agreements that we have entered into with DVI Financial, Inc. and a patent
license with VISX, Incorporated. In the event that we would not be able to
obtain additional excimer lasers and related equipment from these providers, we
believe that other satisfactory sources of supply are available now that the FDA
has approved additional manufacturers of excimer lasers.

Our plan of operation

We believe that our New Mexico center now in operation can sustain its current
operations on current revenue and what we believe will be increased usage of our
center by new clients generated from our advertising and marketing efforts, as
well as general client awareness of the laser vision correction procedure. At
current levels, we are generating a net loss from operations. With current
revenues, we have experienced a continuing increase in the number of surgical
procedures performed in our center primarily, by advertising locally and through
the placement of kiosks in local shopping malls where high pedestrian traffic
exists. Our New Mexico center has the capacity to perform approximately 100 eye
surgery procedures each week and at present, we are performing approximately 20
eye surgeries each week.

We currently generate on average approximately $78,000 per month in gross
revenue and believe that we will require approximately $400,000 in gross revenue
during the next 12 months to maintain our existing operations. We believe that

                                       7

<PAGE>


our cash requirements during the next 12 months will be satisfied through the
operations of the Amaseno dialysis facility which we expect to commence within
60 days.

On August 5, 2004, a subsidiary of the Company, Lasik Acquisition Corp.,
consummated its merger with Salus Holding, Inc. ("Salus"). Pursuant to the
merger agreement, the shareholders of Salus have been issued 2,000,000 shares of
common stock of the Company. The sole shareholder of Salus, Homeland Security
Technology, Inc., was issued 2,000,000 shares of Critical's Common Stock that
approximate 47.3 percent of the outstanding shares of Critical calculated on a
fully diluted basis. In addition, as of August 4, 2004, Ernest B. Remo, former
President and Chairman of the Board of Directors of Salus, has assumed the
position of Chief Executive Officer and Chairman of the Board of Directors of
Critical. Howard Silverman assumed the position of President and member of the
Board of Directors of Critical. Salus is the sole shareholder in Icon Salus
S.r.l., a company formed under the laws of Italy ("Icon Salus").

On November 1, 2004, the Company acquired certain rights to purchase a group of
five dialysis clinics from Icon Veneto srl, an Italian company, pursuant to a
rights purchase agreement. Pursuant to the rights purchase agreement the Company
issued to Icon Veneto 100,000 shares of preferred stock of the Company. The
preferred stock is convertible into 10,000,000 shares of common stock of the
Company. The five dialysis clinics which are the subject of the rights purchase
agreement have established revenues of over Euro 4,000,000 (US$5,250,000).

The following table sets forth, for the years ended July 31, 2004 and 2003,
operating information expressed as a percentage of revenue. The results of
operations data for the years ended July 31, 2004 and 2003 are not necessarily
indicative of the results to be expected for future periods.

                                      Year Ended July 31,    Year Ended July 31,
                                             2004                   2003

Revenues                                             100%                   100%
Operating Costs                                      117%                   107%
Depreciation expense                                  11%                     7%
Interest expense                                       6%                     3%
Write Off of Accounts Payable                         14%                     --
Total Costs and Expenses                             119%                   116%
Net loss                                              19%                    16%

Results of operations
---------------------

Revenues

We derive our revenues directly from the number of laser vision surgical
procedures performed at our center. Procedures performed by our affiliated
doctor generate revenue to us from the physician, who collects a fee from the
patient. Procedures performed by our employed doctor generate revenue directly
to us from the patient. Revenues for the year ended July 31, 2004 totaled
$926,652 as compared to $1,308,640 for the year ended July 31, 2003. Total
revenue is predicated on the number of procedures of laser vision correction we
performed during the period.

                                       8

<PAGE>


Operating Costs

Operating costs consist of doctor fees, royalty fees, medical supplies,
salaries, wages and related costs for general corporate functions. The total
operating costs for the year ended July 31, 2004 was $1.081,423 as compared to
$1,397,238 for the year ended July 31, 2003. As a percentage of revenue,
operating costs equaled 117% of total revenue during the period as compared to
107% for the year ended July 31, 2003. Royalty fees are payable to the licensor
of the excimer laser we use for surgical procedures and is currently $110.00 per
eye.

Non-cash compensation expense

Non-cash compensation expense consists of expenses related to common stock
issued in exchange for services. There was no Non-cash compensation expense for
the years ended July 31, 2004 and July 31, 2003.

Depreciation

Depreciation expense for the year ended July 31, 2004 amounted to $101,706 from
the depreciation of capital items acquired for use in our operations as compared
to $87,922 for the year ended July 31, 2003.

Interest expense

The Company incurred interest expense of $41,267 for the year ended July 31,
2004 as compared to $38,779 for the year ended July 31, 2003. This results from
our financing costs of some of our capital equipment and interest accrued on
delinquent payroll and gross receipt taxes.

Write off of Accounts Payable

During the year ended July 31, 2004 the Company removed $125,370 of accounts
payable for specific balances that were either renegotiated with the vendor or
determined to be not owed by the Company.

Net loss

Our net loss for the year ended July 31, 2004 was $(172,374) as compared to
$(215,299) for the year ended July 31, 2003.

Liquidity and capital resources

Since our inception, we have financed our operations through revenues and
capital raised through the sale of our common stock. In order to effectuate our
business plan as structured we will need to raise significant capital from
external sources. In addition, we intend on raising capital internally through
the increase in the number of procedures we perform. We currently do not have a
credit facility or any commitments for additional financing. If we are unable to
obtain adequate financing from internal or external sources we may be unable to
fully implement our business plan and may be forced to modify our operations.
Cash flows provided by operating activities was $23,288 for the year ended July
31, 2004 as compared to $71,796 for the year ended July 31, 2003. Net cash used
in investing activities was $24,191 for the year ended July 31, 2003; no net
cash was used in investing activities for the year ended July 31, 2004. Net cash
flows provided by (used in) financing activities of ($23,288) in the year ended
July 31, 2004 as compared to $(47,605) for the year ended July 31, 2003.

Management believes that actions are presently being taken to revise the
Company's operating and financial requirements in order to improve the Company's
financial position and operating results. However, given the levels of its cash
resources and working capital deficiency at July 31, 2004, anticipated cash to
be generated by operations will be insufficient to meet anticipated cash
requirements for operations, working capital, and capital expenditures during

                                       9

<PAGE>


2005. Therefore, the Company is seeking additional equity or debt financing, but
there can be no assurance that sufficient additional financing will be
available.

Delinquent Payroll and Gross Receipts Taxes

During the year ended July 31, 2002, the Company became delinquent on employment
taxes payable to the Internal Revenue Service and on gross receipts taxes
payable to the State of New Mexico. The liability for these taxes has been shown
on the balance sheet as of July 31, 2004 and 2003. The Company has entered into
an installment payment arraignment with respect to the Internal Revenue Service.
The Company has started negotiations with the State of New Mexico and expects to
payoff the entire amount of tax owed. During the year ended July 31, 2004, the
Internal Revenue Service filed a lien against all of the assets of the Company
related to the delinquent payroll taxes.

Recently issued accounting standards

The Financial Accounting Standards Board has recently issued several Statements
of Financial Accounting Standards.

In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain Financial
Instruments with Characteristics of both Liabilities and Equity". SFAS No. 150
establishes standards for how an issuer classifies and measures in its statement
of financial position certain financial instruments with characteristics of both
liabilities and equity. SFAS No. 150 requires that an issuer classify a
financial instrument that is within its scope as a liability (or an asset in
some circumstances) because that financial instrument embodies an obligation of
the issuer. SFAS No. 150 is effective for financial instruments entered into or
modified after May 31, 2003 and otherwise is effective at the beginning of the
first interim period beginning after June 15, 2003. SFAS No. 150 is to be
implemented by reporting the cumulative effect of a change in accounting
principle for financial instruments created before the issuance date of SFAS No.
150 and still existing at the beginning of the interim period of adoption.
Restatement is not permitted.

Interpretation No.46R addresses consolidation by business enterprises of
variable interest entities, which have one or both of the following
characteristics: (i) the equity investment at risk is not sufficient to permit
the entity to finance its activities without additional subordinated support
from other parties, which is provided through other interest that will absorb
some or all of the expected losses of the entity; (ii) the equity investors lack
one or more of the following essential characteristics of a controlling
financial interest, the direct or indirect ability to make decisions about the
entities activities through voting rights or similar rights; or the obligation
to absorb the expected losses of the entity if they occur, which makes it
possible for the entity to finance its activities; the right to receive the
expected residual returns of the entity if they occur, which is the compensation
for the risk of absorbing the expected loss.

Interpretation No. 46R, also requires expanded disclosures by the primary
beneficiary (as defined) of a variable interest entity and by an enterprise that
holds a significant variable interest in a variable interest entity but is not
the primary beneficiary. Interpretation No. 46 as revised, applies to small
business issues no later than the end of the first reporting period that ends
after December 15, 2004.

This effective date includes those entities to which Interpretation No. 46R had
previously been applied. However, prior to the required application of
Interpretation No. 46R, a public entity that is a small business issuer shall
apply Interpretation No. 46R or this Interpretation to those entities that are
considered to be special-purpose entities no later than as of the end of the
first reporting period that ends after December 15, 2003.

                                       10

<PAGE>


Interpretation No. 46R may be applied prospectively with a cumulative-effect
adjustment as of the date on which it is first applied or by restating
previously issued financial statements for one or more years with a
cumulative-effect adjustment as of the beginning of the first year restated.

The adoption of these pronouncements will not have a material effect on the
Company's financial position or results of operations.


Item 7.  Financial Statements

The report of the Critical's Independent Auditor, the Critical's financial
statements and notes to financial statements appear herein commencing on Page
F-1.


Item 8.  Changes In and Disagreements with Accountants on Accounting and
Financial

None.

ITEM 8A. CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures. Based on evaluation as of
a date within 90 days of the filing date of this Annual Report on Form 10-KSB,
Critical's principal executive officer/principal accounting officer have
concluded that Critical's disclosure controls and procedures (as defined in
Rules 13a-14(c) and 15d-14(c) under the Securities Exchange Act of 1934 (the
"Exchange Act")) are effective to ensure that information required to be
disclosed by the Company in reports that it files or submits under the Exchange
Act is recorded, processed, summarized and reported within the time periods
specified in Securities and Exchange Commission rules and forms.

(b) Changes in internal controls. There were no significant changes in
Critical's internal controls or in other factors that could significantly affect
these controls subsequent to the date of their evaluation, including any
corrective actions with regard to significant deficiencies and material
weaknesses.

In accordance with the requirements of Section 13 or 15(d) of the Exchange Act,
the registrant has caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                       11

<PAGE>


PART III
Item 9.  Directors, Executive Officers, Promoters and Control Persons of the
Registrant; and Management and Related Stockholder Matters

The table below lists, as of July 31, 2004, the names of the Directors and
Executive Officers of the Company. The Directors have served in their respective
capacities since their election and/or appointment and will serve until the next
Annual Shareholders' Meeting or until a successor is duly elected, unless the
office is vacated in accordance with the Articles/By-Laws of the Company. The
Executive Officers serve at the pleasure of the Board of Directors. All
Directors and Executive Officers are residents and citizens of the United
States.

         Name                            Age         Date Elected or Appointed
         ----                            ---         -------------------------
Ernest B. Remo, Chairman, CEO,            65          August 4, 2004
and Director
Dr. Howard Silverman, Chairman, CEO,      62          May 21, 2001; resigned
                                                      October 28, 2004
Treasurer and Director
Robert S. Helmer, COO                     48          May 21, 2001
Stuart S. Greenberg, Director             71          May 21, 2001
Malcolm Bauer, Director                   58          October 28, 2004

Ernest B. Remo was appointed CEO and Chairman of the Board of Directors of the
Company pursuant to the Merger. Subsequently, On October 28, 2004, Dr. Howard
Silverman resigned his position as President and Treasurer and member of the
Board of Directors. Since 1998, Mr. Remo was the Chief Executive Officer and
Chairman of the Board of Homeland Security Technology, Inc. f/k/a Eyemakers,
Inc. Since 2003, Mr. Remo also served as President and member of the board of
directors of Salus Holding, Inc.

Dr. Howard P. Silverman is Critical's founding shareholder and was its chief
executive officer, chairman of the board, treasurer and a director, since its
inception. He has been involved in various companies developing products and
methods of delivery from the ophthalmic industry. Such companies include
Precision Contract Lens Labs, Inc., Diversified Health Industries, Inc., Hydro
Optics, Inc., Staar Surgical Company and Vision Science, Inc. From 1991 until
the date Lasik was incorporated, Dr. Silverman has been actively involved in a
private consulting business designed to address the capital and corporate
structural needs of companies in the ophthalmic and vision correction
industries. In addition, from 1994 to 1997, Dr. Silverman served as an
investment banking professional at Rickel & Associates, in New York, New York.
Pursuant to the Merger, Dr. Silverman assumed the office of president of the
Company and member of the Board of Directors of the Company. On October 28,
2004, Dr. Silverman resigned his positions on the Board of Directors and as
president of the Company.

Robert S. Helmer has been Lasik's chief operating officer in the Albuquerque,
New Mexico center since the Company began operations in May, 2001. Prior to
joining Lasik in that capacity, Mr. Helmer served as the clinical support
manager from October, 1998 to April, 2001, for TrueVision International, Inc.,
another company that performed eye vision corrective surgical procedures in
Albuquerque, New Mexico. Mr. Helmer is a graduate physician and surgical
assistant with 25 years of medical experience in emergency medicine, laser
medicine, dermatology, cosmetic surgery and hair transplant surgery. From May
1998 until October, 1998, Mr. Helmer was a director and the president of the
International College of Skin-Care Specialists. From October 1991 to October
1995, Mr. Helmer was a surgical assistant with Qualified Emergency Specialists,
Inc., in Cincinnati, Ohio, and from February 1991 to December 1991 was a
surgical assistant and electrologist for Dermatology Associates of Atlanta,
Georgia. Mr. Helmer has been a certified ophthalmic laser technician since
September 1998 and a certified microkeratome technician since June 1999. Mr.

                                       12

<PAGE>


Helmer received his associate of applied science degrees as a physician's
assistant and surgical assistant in 1974 from the Cincinnati Technical College.
He is a member of the American Academy of Physicians Assistants.

Stuart S. Greenberg became one of Lasik's directors in May, 2001. Mr. Greenberg
has worked with a number of leading investment banking and securities firms for
over 35 years, having entered the field in 1960 with Merrill Lynch. From March
2001 to the present, Mr. Greenberg has served as the managing director of the
investment banking division of West America Securities Corp., located in
Westlake Village, California. From March 1999 to February 2001, Mr. Greenberg
was the managing director of R.H. Investment Corp., an investment banking firm
located in Los Angeles, California. From March 1992 to April 1996, he served in
the capacities of chairman of the board and the chief executive officer of
Baraban Securities. During a portion of that same time frame, Mr. Greenberg also
functioned as the chairman of the board and chief executive officer of M.A.
Investment Corp. out of Los Angeles, California. Mr. Greenberg has experience as
branch manager, regional sales manager, as well as national sales manager during
his tenure in the securities and brokerage industry. He received his bachelors
degree from the City College of New York and a banking certification from the
American Banking Institute of Banking in New York, New York.
Malcolm Bauer was appointed to the Board of Directors of the Company on October
28, 2004. For each of the last five years, Mr. Bauer has been working as a
consultant to small cap companies with respect to acquisitions, financings and
investment banking services.

On October 28, 2004, Dr. Howard P. Silverman President and member of the Board
of Directors of the Critical, resigned from his position as President of
Critical and member of the Board of Critical. On October 28, 2004, members of
the Board of Directors of Critical, appointed Malcolm Bauer as a member of the
Board of Directors to serve until a successor is duly elected, unless the office
is vacated in accordance with the Articles/By-Laws of the Company.

Our board of directors is elected at each annual meeting of shareholders. Each
director holds office until his successor is duly elected and qualified or until
his or her earlier resignation or removal.

Officers are elected annually by the Board of Directors and serve at their
direction.

There are no family relationships between any of the officers and/or directors.

Committees

The Board of Directors does not have a Compensation, Audit or Nominating
Committee, and the usual functions of such committees are performed by the
entire Board of Directors.

Compliance with Section 16(a) of the Securities Exchange Act of 1934

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires the
Company's executive officers, directors and persons who own more than ten
percent of a registered class of Critical's equity securities to file certain
reports regarding ownership of, and transactions in, Critical's securities with
the Securities and Exchange Commission (the "SEC"). These officers, directors
and stockholders are also required by SEC rules to furnish Critical with copies
of all Section 16(a) reports that are filed with the SEC.

There were no annual grant of options given to the directors of Critical in
fiscal 2004. To the best of our knowledge, all other Forms 3, 4, and 5 required
to be filed during the year ended July 31, 2004 were not timely filed.

                                       13

<PAGE>
<TABLE>
<CAPTION>


Item 10.  Executive Compensation

The following table sets forth information concerning compensation for services
in all capacities awarded to, earned by or paid to the Company's Chief Executive
Officers in the prior three completed fiscal years (the "Named Officers"). There
are no other executive officers whose compensation exceeded $100,000 in the year
ended July 31, 2004.


                                         Annual Compensation               Long-term Compensation
                                     -------------------------------   ---------------------------------
                                                                               Awards            Payouts
                                                                       ---------------------------------
                                                                       Restricted  Securities
  Name and Principal                                    Other Annual     Stock     Underlying      LTIP       All Other
    Position                 Year    Salary     Bonus   Compensation    Award(s)   Options/SARs   Payouts   Compensation
    --------                 ----    ------     -----   ------------    --------   ------------   -------   ------------
<S>                         <C>        <C>       <C>         <C>          <C>         <C>                       <C>
Howard Silverman
CEO/Chairman/Treasurer/      2002       0         0           0            0           0
Director1                    2003       0         0           0            0           0
                             2004       0         0           0            0           0                          0


Ernest B. Remo
CEO/Chairman/Director2       2004       0         0           0            0           0                          0

1 Dr. Silverman resigned his position as CEO, Chairman, Treasurer and Director
on October 28, 2004.

2 Ernest B. Remo was appointed CEO and Chairman of the Board of Directors of the
Company pursuant to the Merger. Subsequently, On October 28, 2004, Dr. Howard
Silverman resigned his position as President and Treasurer and member of the
Board of Directors.

Director's Compensation

Our directors do not receive any fees or other compensation in connection with
their services as directors.


                           OPTIONS/SAR GRANTS IN 2004

The Company has not granted any options not are any options outstanding to its
executive officers during 2004.

Compensation Committee Interlocks and Insider Participation

The Board of Directors of the Company does not have a compensation committee.
The Board of Directors determines executive compensation, based on corporate
performance and market conditions.

                                       14
</TABLE>

<PAGE>


Stock Option Plan

2002 Stock Award and Incentive Plan

In August 18, 2004, Critical's 2004 Stock Award and Incentive Plan was adopted
and ratified. The 2004 Plan provided for a broad range of awards, including
incentive and non-qualified options, restricted and deferred stock, performance
awards, stock appreciation rights and other types of equity awards.

Item 11.  Security Ownership of Certain Beneficial Owners and Management and
related stockholder matters

The following table sets forth information, as of July 31, 2004, based upon
information obtained from the persons named below, regarding beneficial
ownership of the Company's Common Stock by (i) each current director and nominee
for director of the Company, (ii) each executive officer of the Company named in
the Summary Compensation Table set forth under the caption "Executive
Compensation," below, (iii) each person who is known by the Company to own
beneficially more than 5% of the outstanding shares of its Common Stock and (iv)
all executive officers and directors of the Company as a group.


----------------------- --------------------- --------------------
                        Number of Shares of
Name and Address of         Common Stock
Beneficial Owner         Beneficially Owned     Percent of Class
        (1)                      (2)                  (3)
----------------------- --------------------- --------------------
Ernest B. Remo                         3,000                    *
----------------------- --------------------- --------------------
Dr. Howard Silverman                 140,000                 3.3%
----------------------- --------------------- --------------------
Robert Helmer                        150,000                 3,5%
----------------------- --------------------- --------------------
Malcolm Bauer                              0                    *
----------------------- --------------------- --------------------
Stuart Greenberg                      50,000                 1.2%
----------------------- --------------------- --------------------
SM Gheric Trust1                     950,000                22.5%
----------------------- --------------------- --------------------
Directors & Executive                343,000                 8.1%
Officers as a group
(three persons)
----------------------- --------------------- --------------------
----------------------- --------------------- --------------------

(*) Less than 1%

(1) SM Gheric Trust - The trustee is Bruce M. Silverman and the beneficiaries of
the trust assets are Bruce Silverman, Jeffrey Silverman, and Jodi Silverman.

(2) The number of shares of Common Stock beneficially owned by each person or
entity is determined under the rules promulgated by the SEC. Under such rules,
beneficial ownership includes any shares as to which the person or entity has
sole or shared voting power or investment power and shares which such person or
entity has the right to acquire within sixty days after July 31, 2004. The
inclusion herein of any shares deemed beneficially owned does not constitute an
admission by such person of beneficial ownership of such shares. The information
is based upon information furnished by the person listed.

(3) Assumes with respect to options, the shares underlying only those options
deemed beneficially owned by the shareholder.

                                       15

<PAGE>
<TABLE>
<CAPTION>


The following table sets forth ownership information as of the November 1, 2004,
following the closing of the Merger, with respect to: (i) each current director
or executive officer of the Company; (ii) all directors and executive officers
of the Company as a group, prior to the closing of the Merger and following the
closing of the Merger; and (iii) each person known to the Company to be a
beneficial owner of more than 5% of the outstanding voting securities of the
Company. As of November 1, 2004, there is 9,226,043 shares of common stock
issued and outstanding and no shares of preferred stock outstanding. Each share
of common stock is entitled to one vote.


                           Number of
                           Shares of                 Number of Shares of
                           Common Stock              Common Stock               Percent of Common
Name and Address           Beneficially Owned        Beneficially Owned         Stock Issued
of Beneficial              Prior to Merger           Following Merger           Following Merger
Owner (1)                  Closing(2)                Closing(3)                 Closing(3)
----------------------   --------------            --------------             -------------
<S>                            <C>                   <C>                        <C>
Ernest B. Remo                 3,000                 2,003,000                  21.5%
Dr. Howard Silverman         140,000                   140,000                   1.5%
Robert Helmer                150,000                   150,000                   1.6%
Malcolm Bauer                      0                         0                    -
Stuart Greenberg              50,000                    50,000                    *
Directors and Officers
as a group                   343,000                 2,343,000                  25.1%

(*) Less than 1%

(1) The address for each of Mr. Remo, Mr. Helmer, Mr. Bauer and Mr. Greenberg is
at the Company's offices. The address for Dr. Howard Silverman is
_________________________________.

(2) The number of shares of Common Stock beneficially owned by each person or
entity is determined under the rules promulgated by the SEC. Under such rules,
beneficial ownership includes any shares as to which the person or entity has
sole or shared voting power or investment power and shares which such person or
entity has the right to acquire within sixty days after the record date. The
inclusion herein of any shares deemed beneficially owned does not constitute an
admission by such person of beneficial ownership of such shares. The information
is based upon information furnished by the person listed.

Item 12.  Certain Relationships and Related Transactions

Dr. Howard Silverman, former president and director of the Company made a loan
to the Company totaling $80,985 as of July 31, 2004, and $91,100 as of July 31,
2003. Robert Helmer, the chief operating officer of the Company, made a loan to
the Company totaling $17,494 as of July 31, 2004. The loans bear interest at the
Internal Revenue Service's applicable federal rate. Unpaid interest on the loans
as of July 31, 2004 and 2003 was $7,541 and $4,751, respectively, which is
included in accrued expenses.

During April 2001, the Company acquired certain medical and office equipment
from a related entity via the execution of a promissory note by Dr. Howard
Silverman to the related entity. The Company orally agreed to acquire the
equipment from Dr. Howard Silverman under the same terms. This promissory note
was assigned by the related entity to the Internal Revenue Service. During 2002
this note was assumed and satisfied by an executive officer of the Company.

                                       16
</TABLE>

<PAGE>


During the year ended July 31, 2004, the Company purchased medical equipment
from Dr. Howard Silverman for $200,000 which represented the historical cost
basis of the purchased asset. The purchase price of the this equipment is
included as an account payable to Dr. Howard Silverman as of July 31, 2004.

Item 13.  Exhibits And Reports On Form 8-K

Exhibits:
---------

     31.2 Certification of Chief Executive Officer and Chief Financial Officer
          pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

     32.2 Certification of Chief Executive Officer and Chief Financial
          Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.



Reports on Form 8-K

     Form 8-K filed with the Securities and Exchange Commission by the Company
on November 15, 2004 with respect to the resignation of Dr. Howard Silverman
from the Board of Directors and Presidency of the Company and the appointment of
Malcolm Bauer as a member of the Board of Directors of the Company.

     Form 8-K filed with the Securities and Exchange Commission by the Company
on October 29, 2004 with respect to the name change of the Company to Critical
Care, Inc.

     Form 8-K filed with the Securities and Exchange Commission by the Company
on August 4, 2004 with respect to the merger of Salus Holding, Inc and Lasik
Acquisition Corp.

ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

Aggregate fees for professional services rendered for us by Weinberg & Company,
LLP, for fiscal years ended July 31, 2004 and 2003, are set forth below. The
aggregate fees included in the Audit category are fees billed for the fiscal
years for the audit of our annual financial statements and review of financial
statements and statutory and regulatory filings or engagements. The aggregate
fees included in each of the other categories are billed in the fiscal years.

                                    FISCAL YEAR 2004          FISCAL YEAR 2003
AUDIT FEES                          $ 34,600                  $   -
AUDIT-RELATED FEES                  $   -                     $   -
TAX FEES                            $   -                     $   -
ALL OTHER FEES                      $   -                     $   -
                                    --------                  --------
         TOTAL                      $ 34,600                  $   -
                                    ========                  ========

Audit fees for the fiscal years ended July 31, 2004 and 2003, were for
professional services rendered for the audits of the consolidated financial
statements of the Company, quarterly review of the financial statements included
in Quarterly Reports on Form 10-QSB, and other assistance required to complete
the year end audit of the consolidated financial statements.

As we do not have a formal audit committee (see end of Item 9 above), the
services described above were approved by the Board of Directors under the de
minimus exception provided by Rule 2-01(c)(7)(i)(C) under Regulation S-X.
Further, as we do not have a formal audit committee, the Board of Directors .
approved the procedures of the independent auditor.

                                       17

<PAGE>


                                   SIGNATURES

     In accordance with Section 13 or 15(d) of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized, on November 15, 2004.

                                            CRITICAL CARE, INC.


                                            By:  /s/  Ernest B. Remo
                                               --------------------------------
                                                      Ernest B. Remo
                                                      Chairman of the Board and
                                                      Chief Executive Officer


In accordance with the requirements of the Securities Act of 1933, this
registration statement was signed by the following persons in the capacities and
on the dates stated.




/s/  Ernest B. Remo               Chairman of the Board        November 15, 2004
-----------------------------     and Chief Executive Officer
     Ernest B. Remo               (Principal Executive Officer)

/s/  Stuart Greenberg             Director                     November 15, 2004
-----------------------------
     Stuart Greenberg

/s/  Malcolm Bauer                Director                     November 15, 2004
-----------------------------
     Malcolm Bauer

                                       18

<PAGE>







                       CRITICAL CARE, INC. AND SUBSIDIARY
                           (F/K/A LASIK AMERICA, INC.)
                        CONSOLIDATED Financial Statements

                   fOR THE YEARS ENDED JULY 31, 2004 AND 2003








<PAGE>



                                TABLE OF CONTENTS




REPORT OF REGISTERED PUBLIC ACCOUNTING FIRM    ...........................     1

CONSOLIDATED FINANCIAL STATEMENTS

     Consolidated Balance Sheets as of July 31, 2004 and 2003.............     2

     Consolidated Statements of Operations for the years ended
     July 31, 2004 and 2003 ..............................................     3

     Consolidated Statements of Shareholders' Deficiency for the
     years ended July 31, 2004 and 2003...................................     4

     Consolidated Statements of Cash Flows for the years ended
     July 31, 2004 and 2003 ..............................................     5

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS ...............................6 - 15

<PAGE>


                   REPORT OF REGISTERED PUBLIC ACCOUNTING FIRM



To the Board of Directors
Critical Care, Inc. and Subsidiary

We have audited the accompanying consolidated balance sheets of Critical Care,
Inc. (f/k/a Lasik America, Inc) and Subsidiary (the "Company") as of July 31,
2004 and 2003 and the related consolidated statements of operations, changes in
shareholders' deficiency, and cash flows for the years then ended. These
consolidated financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.

We conducted our audits in accordance with standards of the Public Company
Oversight Board (United States). Those standards require that we plan and
perform the audits to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the consolidated financial position of
Critical Care, Inc. and Subsidiary as of July 31, 2004 and 2003 and the results
of their operations and their cash flows for the years then ended, in conformity
with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern. As discussed in Note 1 to the
consolidated financial statements, the Company has incurred a net loss of
$172,374 for the year ended July 31, 2004, and had a working capital deficiency
of $1,077,845 and a shareholders' deficiency of $873,168 as of July 31, 2004
that raise substantial doubts about its ability to continue as a going concern.
Management's plans in regard to these matters are also described in Note 1. The
consolidated financial statements do not include any adjustments that might
result from the outcome of this uncertainty.


/s/  WEINBERG & COMPANY, P.A.
----------------------------------
     WEINBERG & COMPANY, P.A.

Boca Raton, Florida
November 10, 2004

<PAGE>
<TABLE>
<CAPTION>


                          CRITICAL CARE, INC. AND SUBSIDIARY
                              (F/K/A LASIK AMERICA, INC.)
                              CONSOLIDATED BALANCE SHEETS
                             AS OF JULY 31, 2004 AND 2003



                                                              2004            2003
                                                          ------------    ------------
                                        ASSETS
                                        ------
<S>                                                       <C>             <C>
Current Assets
 Cash                                                     $       --      $       --
 Other current assets                                            5,044           6,107
                                                          ------------    ------------
         Total current assets                                    5,044           6,107

 Property and equipment, net of accumulated
    depreciation of $275,189 and $173,483, respectively        303,156         194,862
                                                          ------------    ------------

TOTAL ASSETS                                              $    308,200    $    200,969
                                                          ============    ============

                       LIABILITIES AND SHAREHOLDERS' DEFICIENCY
                       ----------------------------------------

Current Liabilities
 Bank overdraft                                           $     17,314    $      3,330
 Accounts payable                                              329,721         213,512
 Gross receipts and compensating use tax payable               229,170         164,851
 Payroll taxes payable                                         306,078         229,715
 Accrued penalties and interest on delinquent taxes            120,849          59,900
 Other current liabilities                                      28,117          43,064
 Current portion of long-term debt                              51,640          65,454
                                                          ------------    ------------
         Total Current Liabilities                           1,082,889         779,826

Long-term debt, net of current portion                            --            30,837
Loans payable to officers                                       98,479          91,100
                                                          ------------    ------------

          Total Liabilities                                  1,181,368         901,763
                                                          ------------    ------------

Commitments and Contingencies

Shareholders' Deficiency
 Preferred Stock, $.001 par value, 100,000 shares
    authorized; no shares issued and outstanding                  --              --
 Common stock, $.001 par value, 25,000,000 shares
    authorized; 2,226,043 issued and outstanding                 2,226           2,226
 Additional paid in capital                                 12,639,912      12,639,912
 Accumulated deficit                                       (13,515,306)    (13,342,932)
                                                          ------------    ------------
         Total Shareholders' Deficiency                       (873,168)       (700,794)
                                                          ------------    ------------

Total liabilities and shareholders' deficiency            $    308,200    $    200,969
                                                          ============    ============


             See accompanying notes to consolidated financial statements
                                           2
</TABLE>

<PAGE>


                        CRITICAL CARE, INC AND SUBSIDIARY
                           (F/K/A LASIK AMERICA, INC.)
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                   FOR THE YEARS ENDED JULY 31, 2004 AND 2003



                                                      2004             2003
                                                   -----------      -----------

Revenue                                            $   926,652      $ 1,308,640
                                                   -----------      -----------

Costs and expenses
   Operating costs                                   1,081,423        1,397,238
   Write-off of accounts payable                      (125,370)
   Depreciation                                        101,706           87,922
   Interest                                             41,267           38,779
                                                   -----------      -----------
       Total Costs and Expenses                      1,099,026        1,523,939
                                                   -----------      -----------

Net loss                                           $  (172,374)     $  (215,299)
                                                   ===========      ===========

Basic and diluted net loss per share               $      (.08)     $      (.10)
                                                   ===========      ===========

Shares used to compute basic and
   diluted net loss per share                        2,226,043        2,224,975
                                                   ===========      ===========


           See accompanying notes to consolidated financial statements
                                        3

<PAGE>
<TABLE>
<CAPTION>


                                    CRITICAL CARE, INC. AND SUBSIDIARY
                                        (F/K/A LASIK AMERICA, INC.)
                            CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIENCY
                                FOR THE YEARS ENDED JULY 31, 2004 AND 2003



                                      Common Stock            Additional
                               ---------------------------     Paid-In       Accumulated
                                  Shares         Amount        Capital         Deficit         Total
                               ------------   ------------   ------------   ------------    ------------
<S>                              <C>         <C>            <C>            <C>             <C>
Balance, August 1, 2002           2,216,043   $      2,216   $ 12,619,942   $(13,127,633)   $   (505,475)

Common stock issued for cash         10,000             10         19,970           --            19,980

Net loss for the year                  --             --             --         (215,299)       (215,299)
                               ------------   ------------   ------------   ------------    ------------

Balance, July 31, 2003            2,226,043          2,226     12,639,912    (13,342,932)       (700,794)


Net loss for the year                  --             --             --         (172,374)       (172,374)
                               ------------   ------------   ------------   ------------    ------------

Balance, July 31, 2004            2,226,043   $      2,226   $ 12,639,912   $(13,515,306)   $   (873,168)
                               ============   ============   ============   ============    ============


                        See accompanying notes to consolidated financial statements
                                                     4
</TABLE>

<PAGE>
<TABLE>
<CAPTION>


                                    CRITICAL CARE, INC. AND SUBSIDIARY
                                        (F/K/A LASIK AMERICA, INC.)
                                  CONSOLIDATED STATEMENTS OF CASH FLOWS
                                FOR THE YEARS ENDED JULY 31, 2004 AND 2003



                                                                                     2004         2003
                                                                                   ---------    ---------
<S>                                                                                <C>          <C>
Cash flows from operating activities
 Net loss                                                                          $(172,374)   $(215,229)
 Adjustments to reconcile net loss to net cash provided by operating activities:
      Depreciation                                                                   101,706       87,922
   Changes in operating assets and liabilities:
    Decrease / (increase) in:
      Prepaid expenses and other current assets                                        1,063        6,719
    Increase / (decrease) in:
      Accounts payable                                                               (93,791)       6,355
      Gross receipts and compensating tax payable                                     64,319       76,062
      Payroll tax payable                                                             76,363       69,341
      Accrued penalties and interest on delinquent taxes                              60,949       42,428
      Other liabilities                                                              (14,947)      (1,732)
                                                                                   ---------    ---------
          Net Cash Provided By Operating Activities                                   23,288       71,796
                                                                                   ---------    ---------

CASH FLOWS FROM INVESTING ACTIVITIES
 Purchase of medical equipment                                                          --        (24,191)
                                                                                   ---------    ---------
          Net Cash Used In Investing Activities                                         --        (24,191)
                                                                                   ---------    ---------

Cash flows from financing activities
 Bank overdraft                                                                       13,984       (7,686)
 Net borrowing from officers                                                           7,379       41,100
 Proceeds from issuance of common stock                                                 --         19,980
 Repayments of long-term debt                                                        (44,651)    (100,999)
                                                                                   ---------    ---------
          Net Cash Used In Financing Activities                                      (23,288)     (47,605)
                                                                                   ---------    ---------

Net Increase/(Decrease) In Cash                                                         --           --
Cash at beginning of year                                                               --           --
                                                                                   ---------    ---------
Cash at end of year                                                                $    --      $    --
                                                                                   =========    =========

SUPPLEMENTAL DISCLOSURES
 Cash paid during the period for
     Interest                                                                      $   1,313    $   5,923
                                                                                   =========    =========

 Schedule of Noncash Investing and Financing Transactions
      Accounts payable incurred to purchase medical equipment                      $ 210,000    $    --
                                                                                   =========    =========


                        See accompanying notes to consolidated financial statements
                                                     5
</TABLE>

<PAGE>


                       CRITICAL CARE, INC. AND SUBSIDIARY
                           (F/K/A LASIK AMERICA, INC.)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                          AS OF JULY 31, 2004 AND 2003


NOTE 1    ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES
------    ------------------------------------------------

          Organization and Business
          -------------------------

          Critical Care, Inc. (the "Company") was incorporated in the State of
          Nevada on March 21, 2001. The Company operates an ophthalmic laser
          vision correction center in Albuquerque, New Mexico. On October 26,
          2004, the Company formally changed its name from Lasik America, Inc.
          to Critical Care, Inc.

          Going Concern
          -------------

          The accompanying financial statements have been prepared assuming that
          the Company will continue as a going concern. The Company had a net
          loss of $172,374 for the year ended July 31, 2004, and a working
          capital deficiency of $1,077,845 and shareholders' deficiency of
          $873,168 as of July 31, 2004 which raises substantial doubts about its
          ability to continue as a going concern. The financial statements do
          not include adjustments that might result from the outcome of this
          uncertainly.

          Management believes that actions are presently being taken to revise
          the Company's operating and financial requirements in order to improve
          the Company's financial position and operating results. However, given
          the levels of its cash resources and working capital deficiency at
          July 31, 2004, anticipated cash to be generated by operations will be
          insufficient to meet anticipated cash requirements for operations,
          working capital, and capital expenditures during 2005. Therefore, the
          Company is seeking additional equity or debt financing, but there can
          be no assurance that sufficient additional financing will be
          available.

          Principles of Consolidation
          ---------------------------

          The financial statements included the accounts of Critical Care, Inc
          and its wholly owned subsidiary. All significant intercompany
          transactions and balances have been eliminated in consolidation.

          Financial Instruments
          ---------------------

          Statement of Financial Accounting Standards No. 107 "Disclosure about
          Fair Value of Financial Instruments" requires disclosures of
          information about the fair value of certain financial instruments for
          which it is practicable to estimate the value. For purposes of this
          disclosure, the fair value of a financial instrument is the amount at
          which the instrument could be exchanged in a current transaction
          between willing parties other than in a forced sale of liquidation.

                                       6

<PAGE>


                       CRITICAL CARE, INC. AND SUBSIDIARY
                           (F/K/A LASIK AMERICA, INC.)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                          AS OF JULY 31, 2004 AND 2003


          The carrying amounts reported in the balance sheet for cash, bank
          overdraft, accounts receivable, accounts payable, accrued liabilities,
          taxes payable and other current liabilities approximate fair value due
          to the immediate short-term maturity of these financial instruments.

          The fair value of the Company's long-term debt approximates the
          carrying amount based on the current rates offered to the Company for
          debt of the same remaining maturities with similar collateral
          requirements.

          Property and Equipment
          ----------------------

          Property and equipment are recorded at cost. Depreciation is
          calculated on a straight-line basis over the estimated useful lives of
          the depreciable assets which range from three to four years.

          Revenue Recognition
          -------------------

          Revenues are generated by the vision correction procedures performed
          at the Company's laser center. Follow-up corrective procedures for
          customer satisfaction, consisting of re-treatment, are performed when
          necessary. Facility fees are derived from the use of the Company's
          equipment by affiliate doctors who pay the Company a standard fee per
          procedure. The Company recognizes revenues when the vision correction
          procedures are performed. Discounts are negotiated during the
          evaluation process and are recorded at the time revenues are
          recognized and the service is performed.

          Concentration Risk
          ------------------

          The Company's revenues are generated by the vision correction
          procedures performed at its laser center in Albuquerque, New Mexico.
          If the demand for this procedure decreased or if the Company's ability
          to continue to provide this service was impaired, the Company's
          revenue source would be severely impacted.

          The Company is dependent on a small number of manufacturers for the
          supply of its excimer laser and related equipment. If any of these
          manufacturers were unable to continue to provide this equipment, the
          Company's revenue generating ability would be severely impacted.

          Earnings (Loss) Per Share
          -------------------------

          Basic earnings (loss) per share is calculated by dividing the earnings
          net (loss) available to common shareholders by the weighted average
          number of common shares outstanding during the year. Diluted earnings

                                        7

<PAGE>


                       CRITICAL CARE, INC. AND SUBSIDIARY
                           (F/K/A LASIK AMERICA, INC.)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                          AS OF JULY 31, 2004 AND 2003


          per share is calculated assuming the issuance of common shares
          resulting from the exercise of stock options and warrants. Dilutive
          securities are not included in the calculation of loss per share
          because their effect would have been anti-dilutive. Accordingly, basic
          and diluted loss per share is ($.08) for the year ended July 31, 2004
          and ($.10) for the year ended July 31, 2003.

          Income Taxes
          ------------

          The Company accounts for income taxes using the asset and liability
          method. Under the asset and liability method, deferred income taxes
          are recognized for the tax consequences of "temporary differences" by
          applying enacted statutory tax rates applicable to future years to
          differences between the financial statement carrying amounts and the
          tax bases of existing assets and liabilities. Deferred tax assets are
          reduced by a valuation allowance when, in the opinion of management,
          it is more likely than not that some portion or all of the deferred
          tax assets will not be realized.

          Use of Estimates
          ----------------

          The preparation of financial statements in conformity with accounting
          principles generally accepted in the United States of America requires
          management to make estimates and assumptions that affect the reported
          amounts of assets and liabilities and disclosure of contingent assets
          and liabilities at the date of the financial statements and the
          reported amounts of revenues and expenses during the reporting period.
          Actual results could differ from those estimates.

          Stock-Based Compensation
          ------------------------

          Statement of Financial Accounting Standards No. 123, "Accounting for
          Stock-Based Compensation" (SFAS No. 123), establishes a fair value
          method of accounting for stock-based compensation plans and for
          transactions in which an entity acquires goods or services from
          non-employees in exchange for equity instruments. SFAS No. 123 also
          encourages, but does not require companies to record compensation cost
          stock-based employee compensation. SFAS No. 123 was amended by SFAS
          No. 148, which now requires companies to disclose in interim financial
          statements the pro forma effect on net income (loss) and net income
          (loss) per common share of the estimated fair market value of stock
          options or warrants issued to employees. The Company has chosen to
          continue to account for stock-based compensation utilizing the
          intrinsic value method prescribed in Accounting Principles Board
          Opinion No. 25, "Accounting for Stock Issued to Employees", with pro
          forma disclosures of net income (loss) as if the fair value method had
          been applied. Accordingly, compensation cost for stock options is
          measured as the excess, if any, of the fair market price of the
          Company's stock at the date of grant over the amount an employee must
          pay to acquire the stock.

                                        8

<PAGE>


                       CRITICAL CARE, INC. AND SUBSIDIARY
                           (F/K/A LASIK AMERICA, INC.)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                          AS OF JULY 31, 2004 AND 2003


          Recent Accounting Pronouncements
          --------------------------------

          The Financial Accounting Standards Board has recently issued several
          Statements of Financial Accounting Standards.

          In January 2003, the Financial Accounting Standards Board ("FASB")
          issued Interpretation No. 46, "Consolidation of Variable Interest
          Entities", an interpretation of Accounting Research Bulletin ("ARB")
          No. 51 "Consolidated Financial Statement". In December 2003, the FASB
          issued a revised version of FIN 46 (FIN 46R) that replaced the
          original FIN 46.

          Interpretation No.46R addresses consolidation by business enterprises
          of variable interest entities, which have one or both of the following
          characteristics: (i) the equity investment at risk is not sufficient
          to permit the entity to finance its activities without additional
          subordinated support from other parties, which is provided through
          other interest that will absorb some or all of the expected losses of
          the entity; (ii) the equity investors lack one or more of the
          following essential characteristics of a controlling financial
          interest, the direct or indirect ability to make decisions about the
          entities activities through voting rights or similar rights; or the
          obligation to absorb the expected losses of the entity if they occur,
          which makes it possible for the entity to finance its activities; the
          right to receive the expected residual returns of the entity if they
          occur, which is the compensation for the risk of absorbing the
          expected loss.

          Interpretation No. 46R, also requires expanded disclosures by the
          primary beneficiary (as defined) of a variable interest entity and by
          an enterprise that holds a significant variable interest in a variable
          interest entity but is not the primary beneficiary. Interpretation No.
          46 as revised, applies to small business issues no later than the end
          of the first reporting period that ends after December 15, 2004.

          This effective date includes those entities to which Interpretation
          No. 46R had previously been applied. However, prior to the required
          application of Interpretation No. 46R, a public entity that is a small
          business issuer shall apply Interpretation No. 46R or this
          Interpretation to those entities that are considered to be
          special-purpose entities no later than as of the end of the first
          reporting period that ends after December 15, 2003.

          Interpretation No. 46R may be applied prospectively with a
          cumulative-effect adjustment as of the date on which it is first
          applied or by restating previously issued financial statements for one
          or more years with a cumulative-effect adjustment as of the beginning
          of the first year restated.

                                        9

<PAGE>
<TABLE>
<CAPTION>


                       CRITICAL CARE, INC. AND SUBSIDIARY
                           (F/K/A LASIK AMERICA, INC.)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                          AS OF JULY 31, 2004 AND 2003


          In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain
          Financial Instruments with Characteristics of both Liabilities and
          Equity". SFAS No. 150 establishes standards for how an issuer
          classifies and measures in its statement of financial position certain
          financial instruments with characteristics of both liabilities and
          equity. SFAS No. 150 requires that an issuer classify a financial
          instrument that is within its scope as a liability (or an asset in
          some circumstances) because that financial instrument embodies an
          obligation of the issuer. SFAS No. 150 is effective for financial
          instruments entered into or modified after May 31, 2003 and otherwise
          is effective at the beginning of the first interim period beginning
          after June 15, 2003. SFAS No. 150 is to be implemented by reporting
          the cumulative effect of a change in accounting principle for
          financial instruments created before the issuance date of SFAS No. 150
          and still existing at the beginning of the interim period of adoption.
          Restatement is not permitted.

          The Company does not expect that the adoption of these pronouncements
          will have a material effect on the Company's financial position or
          results of operations.

          Advertising
          -----------

          The Company expenses advertising costs as incurred. Advertising
          expense totaled $75,584 and $165,964 for the years ended July 31, 2004
          and 2003, respectively.

NOTE 2    PROPERTY AND EQUIPMENT
------    ----------------------

          Property and equipment consist of the following as of July 31, 2004
          and 2003:

                                                                   2004          2003
                                                                ----------    ----------
          <S>                                                   <C>           <C>
          Medical equipment                                     $  438,272    $  228,272
          Assets obtained through capital lease obligation         105,019       105,019
          Leasehold improvements                                    23,382        23,382
          Office equipment, furniture and fixtures                  11,672        11,672
                                                                ----------    ----------
                                                                   578,345       368,345
          Less accumulated depreciation                           (275,189)     (173,483)
                                                                ----------    ----------
             Net property and equipment                         $  303,156    $  194,862
                                                                ==========    ==========

                                             10
</TABLE>

<PAGE>


                       CRITICAL CARE, INC. AND SUBSIDIARY
                           (F/K/A LASIK AMERICA, INC.)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                          AS OF JULY 31, 2004 AND 2003


NOTE 3    LONG-TERM DEBT
------    --------------

          Long-term debt consists of the following as of July 31, 2004 and July
          31, 2003:

                                                        July 31,     July 31,
                                                          2004         2003
                                                        --------     --------

          The Company's former CEO entered into a
          loan agreement for the acquisition of
          the excimer laser used in the operations
          of the Company. By oral agreement, the
          Company acquired the laser from the
          former CEO under terms which mirrored
          the original loan agreement. This loan
          bore interest at 10% per annum with
          interest and principal payable in
          monthly installments of approximately
          $6,200. The note was secured by a first
          security interest in the excimer laser
          and related equipment. (The note was
          paid off in February 2004.)                   $   -        $ 30,174

          Capital lease obligation bearing
          interest at 5.22% per annum with
          interest and principal payable in
          monthly installments of $3,158. The
          obligation expires in April 2005 with a
          $1 buyout. The lease relates to an
          upgrade of laser equipment with net book
          value of $41,570 at July 31, 2004.


                                                          51,640       66,117
                                                        --------     --------
                                                          51,640       96,291
         Less: Current portion                           (51,640)     (65,454)
                                                        --------     --------

                                                        $   -        $ 30,837
                                                        ========     ========


NOTE 4    COMMITMENTS AND CONTINGENCIES
------    -----------------------------

          Lease Commitments
          -----------------

          The Company has several operating leases that are on a month to month
          basis. The Company also entered an agreement to lease its existing
          facility under a non-cancelable operating lease for three years
          beginning in February 2003. The minimum future obligations under this
          agreement is as follows:

                                       11

<PAGE>


                       CRITICAL CARE, INC. AND SUBSIDIARY
                           (F/K/A LASIK AMERICA, INC.)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                          AS OF JULY 31, 2004 AND 2003


                         Year ending July 31,
                       ------------------------
                                2005                  $  29,453
                                2006                     15,015
                                                      ---------

                                                      $  44,468
                                                      =========

          Rent expense for the years ended July 31, 2004 and 2003 was $61,745
          and $30,577, respectively.

          Litigation
          ----------

          On or about December 17, 2002, a charge of discrimination against the
          Company was filed with the United States Equal Employment Opportunity
          Commission (the "EEOC") by Donna L. Smith-Howard, alleging that she
          was terminated without a valid reason and denied severance benefits in
          violation of Title VII of the Civil Rights Act of 1964 as amended.

          The Company has responded to and denied the charge, stating that Ms.
          Smith-Howard, a probationary employee, was terminated due to the
          elimination of her position because of a lack of sufficient business
          that would justify her position, and the duties assigned to her were
          then reassigned to another employee with greater seniority.

          The Company also denied Ms. Smith-Howard's factually incorrect
          allegations that another employee was given a severance package and
          that she was replaced by another employee. This matter was under
          investigation and was pending in the EEOC office located at 1919 Smith
          Street, Houston, Texas, 77002. The Company vigorously contested the
          charge, and it received a favorable outcome and a finding of no
          probable cause by the EEOC.

          A complaint to recover damages for breach of contract was filed
          against the Company on March 31, 2003 by Mary Ratchford, a former
          employee. Ms. Ratchford contends that she was fired as an employee in
          spite of an employment contract that she had with the Company. The
          Company has responded to the charge stating that she violated her
          contract through non-performance and dishonesty. The case is presently
          in the discovery stage. The Company may, in the near future, file a
          counterclaim against Ms. Ratchford. The Company intends to vigorously
          contest the charge and it expects a favorable outcome.

                                       12

<PAGE>


                       CRITICAL CARE, INC. AND SUBSIDIARY
                           (F/K/A LASIK AMERICA, INC.)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                          AS OF JULY 31, 2004 AND 2003


          Delinquent Payroll and Gross Receipts Taxes
          -------------------------------------------

          During the year ended July 31, 2002, the Company became delinquent on
          employment taxes payable to the Internal Revenue Service and on gross
          receipts taxes payable to the State of New Mexico. The liability for
          these taxes has been shown on the balance sheet as of July 31, 2004
          and 2003. The Company has started negotiations with both the Internal
          Revenue Service and the State of New Mexico to establish payment plans
          and expects to payoff the entire amount of taxes owed. During the year
          ended July 31, 2004, the Internal Revenue Service filed a lien against
          all the assets of the Company related to these delinquent payroll
          taxes.


NOTE 5    SHAREHOLDERS' EQUITY
------    --------------------

          During the year ended July 31, 2003, the Company issued 10,000 shares
          of common stock in exchange for $19,980 cash.


NOTE 6    INCOME TAXES
------    ------------

          Deferred income taxes reflect the net tax effects of the temporary
          differences between the carrying amounts of assets and liabilities for
          financial reporting and the amounts used for income tax purposes. The
          tax effect of temporary differences consisted of the following as of
          July 31, 2004 and 2003.

                                                  2004           2003
                                               ----------     ----------

          Deferred tax assets:
          Net operating loss carryforwards     $  503,900     $  435,600
                                               ----------     ----------

          Gross deferred tax assets               503,900        435,600

              Less valuation allowance           (503,900)      (435,600)
                                               ----------     ----------

             Deferred tax assets               $     -        $     -
                                               ==========     ==========

          Realization of deferred tax assets is dependent upon sufficient future
          taxable income during the period that deductible temporary differences
          and carryforwards are expected to be available to reduce taxable
          income. As the achievement of required future taxable income is
          uncertain, the Company recorded a valuation allowance. Additionally,
          net operating loss carryforwards may be limited because of changes in
          ownership.

                                       13

<PAGE>
<TABLE>
<CAPTION>


                       CRITICAL CARE, INC. AND SUBSIDIARY
                           (F/K/A LASIK AMERICA, INC.)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                          AS OF JULY 31, 2004 AND 2003


          As of July 31, 2004 and 2003, the Company has net operating loss
          carryforwards for both federal and state income tax purposes of
          approximately $1,353,842 and $1,091,299, respectively. Federal net
          operating loss carryforwards begin to expire in 2024; state net
          operating loss carryforwards begin to expire in 2006.

          A reconciliation of the effective tax rates with the federal statutory
          rate is as follows for the period ended July 31, 2003 and 2002:

                                                                 2004         2003
                                                               --------     --------
          <S>                                                  <C>          <C>
          Beginning deferred rate                              $   -        $   -
          Federal income tax benefit at 35% statutory rate      (60,000)     (75,000)
          State income taxes at 4.8% statutory rate              (8,300)     (11,000)
          Change in valuation allowance                          68,300       86,000
                                                               --------     --------


          Deferred tax assets                                  $   -        $   -
                                                               ========     ========

NOTE 7    RELATED PARTY TRANSACTIONS
------    --------------------------

          The former CEO of the Company made a loan to the Company totaling
          $98,479 as of July 31, 2004, and $91,100 as of July 31, 2003. The loan
          bears interest at the Internal Revenue Service's applicable federal
          rate. Unpaid interest on the loan as of July 31, 2004 and 2003 is
          $7,541 and $4,751, respectively which is included in accrued expenses.

          During April 2001, the Company acquired certain medical and office
          equipment from a related entity via the execution of a promissory note
          by the former CEO to the related entity. The Company orally agreed to
          acquire the equipment from the former CEO under the same terms. This
          promissory note was assigned by the related entity to the Internal
          Revenue Service. During 2002 this note was assumed and satisfied by an
          executive officer of the Company. (See Note 3).

          During the year ended July 31, 2004, the Company purchased medical
          equipment from its former CEO for $210,000, which represented the
          historical cost basis of the purchased assets. The purchase price of
          this equipment is included in accounts payable as of July 31, 2004.

NOTE 8    STOCK WARRANTS
------    ---------------

          During the period ended July 31, 2002, the Company issued 125,000
          warrants to an existing shareholder. The warrants granted the
          shareholder the right to purchase, for $7.20, an additional share of
          common stock for each common share currently owned by the shareholder

                                       14
</TABLE>

<PAGE>


                       CRITICAL CARE, INC. AND SUBSIDIARY
                           (F/K/A LASIK AMERICA, INC.)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                          AS OF JULY 31, 2004 AND 2003


          and expire in 2006. The value of warrants at the time of issuance was
          nominal since there was no active market for either the stock or the
          warrants. As of July 31, 2004, all of the warrants remained
          outstanding.


NOTE 9    WRITE-OFF OF ACCOUNTS PAYABLE
------    -----------------------------

          During the year ended July 31, 2004 the Company removed $125,370 of
          accounts payable for specific balances that were either renegotiated
          with the vendor or determined to be not owed by the Company.


NOTE 10   SUBSEQUENT EVENTS
-------   -----------------

          On August 3, 2004, the Company consummated a merger of its
          wholly-owned subsidiary, Lasik Acquisition Corp. and Salus Holdings,
          Inc., a New York corporation ("Salus") pursuant to the terms of an
          Agreement and Plan of Merger dated May 11, 2004. Pursuant to the terms
          of Merger Agreement, the sole shareholder of Salus, was issued
          2,000,000 shares of common stock of the Company (47.3% of all of the
          issued and outstanding shares of the Company) in exchange for all of
          the issued and outstanding shares of Salus. Salus, through its wholly
          owned subsidiary, Icon Salus, S.r.l. is developing dialysis clinics in
          Italy. For financial statement accounting purposes, it is intended
          that the merger will be accounted for as a purchase.

          On August 18, 2004, the Company's 2004 Stock Award & Incentive Plan
          was approved by the Board of Directors. A total of 5,000,000 shares of
          common stock were reserved and available for grant under the 2004
          Plan. As of November 1, 2004, 5,000,000 shares were issued pursuant to
          the plan to five corporations for consulting services provided to the
          acquired company.

          On October 26, 2004, the Company formally changed its name from Lasik
          America, Inc. to Critical Care, Inc.

          On November 1, 2004, the Company acquired certain rights to purchase a
          group of five dialysis clinics from Icon Veneto srl, an Italian
          company, pursuant to a rights purchase agreement. Pursuant to the
          rights purchase agreement the Company issued to Icon Veneto 100,000
          shares of preferred stock of the Company. The preferred stock is
          convertible into 10,000,000 shares of common stock of the Company.

                                       15